Page 7 - CCV-AR-2015-MASTER.indd
P. 7
Research Highlights
Health Policy &
Translation Group HIGHLIGHTS
• Evaluation of the introduction of new immunizers (i.e.
Pharmacists) on vaccine uptake in Nova Scotia and in
CCfV has the distinctive pleasure to host New Brunswick
a cluster of independent university- • Evaluation of new vaccine (e.g. HPV, rotavirus) delivery
based research faculty and trainees with systems and uptake
expertise in economics, epidemiology, • Condition of Service: what do health care workers think?
ethics, law, medical anthropology, • Developing strategies to reduce vaccination pain in
Canada and in low income countries
philosophy, political science and • Determining the safety and acceptability of maternal
sociology. immunization
• Factors contributing to vaccine hesitancy and lack of
Working together with community groups, confi dence in vaccine safety
national and international agencies such as the • Ebola: developing culturally sensitive strategies for
National Advisory Committee on Immunization international relief eff orts and clinical trials in west Africa
and the World Health Organization, with public • Ebola: vaccine clinical trials in Canada
health offi cials, research scientists and clinicians, • Access to information about assay methods used to
the Health Policy and Translation Group lends evaluate safety and eff ectiveness of vaccines
critical socio-cultural, economic, ethical, and
legal analyses about vaccine development and • Investigating vaccine safety standards in developing
countries, and the capacity for these countries to
clinical trials, knowledge, attitudes and practices, implement immunization programs
and immunization programs in Canada and in • Assessing Bill C-17 regulating drugs for patient safety
other high, middle and low income countries.
• Finding sustainable health solutions in low income
countries
• MicroResearch training and research projects in Kenya,
Uganda and Tanzania
• Policies on vaccine research engagement with
communities
• Policies on interdisciplinary vaccine research
5 5
Annual Repor
Annual Report | 2014-15 t | 2014-15
Health Policy &
Translation Group HIGHLIGHTS
• Evaluation of the introduction of new immunizers (i.e.
Pharmacists) on vaccine uptake in Nova Scotia and in
CCfV has the distinctive pleasure to host New Brunswick
a cluster of independent university- • Evaluation of new vaccine (e.g. HPV, rotavirus) delivery
based research faculty and trainees with systems and uptake
expertise in economics, epidemiology, • Condition of Service: what do health care workers think?
ethics, law, medical anthropology, • Developing strategies to reduce vaccination pain in
Canada and in low income countries
philosophy, political science and • Determining the safety and acceptability of maternal
sociology. immunization
• Factors contributing to vaccine hesitancy and lack of
Working together with community groups, confi dence in vaccine safety
national and international agencies such as the • Ebola: developing culturally sensitive strategies for
National Advisory Committee on Immunization international relief eff orts and clinical trials in west Africa
and the World Health Organization, with public • Ebola: vaccine clinical trials in Canada
health offi cials, research scientists and clinicians, • Access to information about assay methods used to
the Health Policy and Translation Group lends evaluate safety and eff ectiveness of vaccines
critical socio-cultural, economic, ethical, and
legal analyses about vaccine development and • Investigating vaccine safety standards in developing
countries, and the capacity for these countries to
clinical trials, knowledge, attitudes and practices, implement immunization programs
and immunization programs in Canada and in • Assessing Bill C-17 regulating drugs for patient safety
other high, middle and low income countries.
• Finding sustainable health solutions in low income
countries
• MicroResearch training and research projects in Kenya,
Uganda and Tanzania
• Policies on vaccine research engagement with
communities
• Policies on interdisciplinary vaccine research
5 5
Annual Repor
Annual Report | 2014-15 t | 2014-15
